search
The "NRG Trial Portfolio" event focuses on NRG Oncology, a non-profit research organization uniting renowned entities like the National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG). The speaker outlines NRG's lung portfolio, emphasizing trials for early-stage inoperable patients, including small cell and mesothelioma trials. The Pacific 4 trial, a foundation trial through industry collaboration, is highlighted for its popularity.
The presentation delves into the unresectable 3A group, proton versus photon trials, and metastatic settings, showcasing a standard of care with systemic therapy and local consolidative therapy. The focus then shifts to mesothelioma, specifically LU006, detailing adjuvant radiation after pleurectomy decortication, with intricate intensity-modulated imRT. The trial aims to improve overall survival, incorporating surgery credentialing and central review for radiation plans.